Investigation the Relationship Between Myonectin Levels and Both Lipid Profiles and Liver Function Tests in Diabetic Nephropathy Patients

Myonectin, or CTRP12, is a relatively recent adipokine—a protein released by adipose tissue that has gained interest in the context of metabolic health, including its possible implications in diabetic complications. Volunteers were divided into three groups, healthy subjects as controls (group A), they don't suffer from any disease, patients with T2D without nephropathy  (group B) and T2D with nephropathy (group C), the age ranges between (35-70) years and the average duration disease of T2D (5-25) years, attending to the AL-Kindi teaching hospital, Baghdad Iraq. There was a highly significant increase P ≤ 0.01 of FBS, Insulin level, HOMA-IR, HbA1c, TC, TG, HDL and TSB among different groups (T2D with nephropathy, T2D without nephropathy, and control), a highly significant increase P ≤ 0.01 of myonectin levels among different groups. There was no significant difference present in AST U/L, and ALP U/L. A statistically significant increase in ALT U/L when compared with the control group. Conclusion: Levels of serum myonectin were significantly higher in patients with (T2D without nephropathy) as compared with ( T2D with nephropathy) and the control group.